Literature DB >> 25455092

GFR decline as an end point for clinical trials in CKD: a view from Europe.

Peter G M Mol, Romaldas Maciulaitis, Thorsten Vetter.   

Abstract

Mesh：

Year:  2014        PMID： 25455092     DOI： 10.1053/j.ajkd.2014.10.001

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  6 in total

1.  Guidelines for clinical evaluation of chronic kidney disease : AMED research on regulatory science of pharmaceuticals and medical devices.

Authors:  Eiichiro Kanda; Naoki Kashihara; Kunihiro Matsushita; Tomoko Usui; Hirokazu Okada; Kunitoshi Iseki; Kenichi Mikami; Tetsuhiro Tanaka; Takashi Wada; Hirotaka Watada; Kohjiro Ueki; Masaomi Nangaku
Journal:  Clin Exp Nephrol       Date:  2018-12       Impact factor: 2.801

2.  Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes.

Authors:  Toshiaki Ohkuma; Min Jun; John Chalmers; Mark E Cooper; Pavel Hamet; Stephen Harrap; Sophia Zoungas; Vlado Perkovic; Mark Woodward
Journal:  Clin J Am Soc Nephrol       Date:  2019-06-03       Impact factor: 8.237

3.  Soluble urokinase-type plasminogen activator receptor (suPAR) is a risk indicator for eGFR loss in kidney transplant recipients.

Authors:  Ulrich Jehn; Katharina Schütte-Nütgen; Ute Henke; Hermann Pavenstädt; Barbara Suwelack; Stefan Reuter
Journal:  Sci Rep       Date:  2021-02-12       Impact factor: 4.379

4.  Early, Noninvasive Clinical Indicators of Kidney Prognosis in Primary Nephrotic Syndrome: A Retrospective Exploratory Study.

Authors:  Keiji Fujimoto; Takatoshi Haraguchi; Sho Kumano; Keita Yamazaki; Nobuhiko Miyatake; Kanae Nomura; Kiyotaka Mukai; Kazuaki Okino; Norifumi Hayashi; Hiroki Adachi; Hitoshi Yokoyama; Yasuo Iida; Kengo Furuichi
Journal:  Int J Nephrol       Date:  2022-08-09

5.  Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.

Authors:  Julio Rosenstock; Vlado Perkovic; John H Alexander; Mark E Cooper; Nikolaus Marx; Michael J Pencina; Robert D Toto; Christoph Wanner; Bernard Zinman; David Baanstra; Egon Pfarr; Michaela Mattheus; Uli C Broedl; Hans-Juergen Woerle; Jyothis T George; Maximilian von Eynatten; Darren K McGuire
Journal:  Cardiovasc Diabetol       Date:  2018-03-14       Impact factor: 9.951

6.  Prognostic Value of Growth Differentiation Factor 15 in Kidney Donors and Recipients.

Authors:  Ulrich Jehn; Katharina Schütte-Nütgen; Ute Henke; Joachim Bautz; Hermann Pavenstädt; Barbara Suwelack; Stefan Reuter
Journal:  J Clin Med       Date:  2020-05-03       Impact factor: 4.241
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.